Thursday, January 16, 2020 1:57:27 PM
Page 10 from the CLRB data presentation in my last post below.
It shows trial result numbers better than CAR-T trials and on-going CLR131 ORR as good and becoming better than MM drugs now being sold when they were at this stage of CLRB’s clinical trials- ON SEVERAL FORM OF CANCER, NOT JUST MM!
The FDA has approved many popular MM drugs such as Pomalyst which had an ORR of just 30% in its clinical trials. ( SEE PAGE 9 of presentation linked below) Now Pomalyst is selling at $17,000 for 21 4mg pills = one month dosing for use with Decadron once a week.
According to page 10 of the presentation ( https://seekingalpha.com/article/4316868-cellectar-biosciences-clrb-presents-biotech-showcase-2020-slideshow?dr=1&source=2800:read_now&utm_medium=email&utm_source=seeking_alpha ) CLR131 has already met and exceeded Pomalyst’s ORR IN CLINICAL TRIALS results (page 9) before Celegene was approved to market Pomalyst.
I BELIEVE CLRB WILL BE BOUGHT OUT (M&A) BY BIG PHARMA WITHIN ONE YEAR FOR REASONS REFLECTED IN LINK ABOVE OF CLRB’s PUBLIC PRESENTATION SCHEDULED FOR 2-19-20.
Cellectar Biosciences to Host a CLR 131 Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020
BY GlobeNewswire
— 8:00 AM ET 01/09/2020
FLORHAM PARK, N.J., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences ( CLRB
), Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it will host a Clinical Data Call on Wednesday, February 19, 2020 at 10:30 am Eastern Time.
Recent CLRB News
- Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom’s Macroglobulinemia • GlobeNewswire Inc. • 08/26/2024 10:40:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/23/2024 09:15:38 PM
- Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq • GlobeNewswire Inc. • 08/23/2024 09:00:00 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 08/14/2024 11:15:55 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2024 09:00:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 10:45:19 AM
- Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update • GlobeNewswire Inc. • 08/13/2024 10:40:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 09:00:47 PM
- UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024 • GlobeNewswire Inc. • 08/08/2024 09:15:14 PM
- Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024 • GlobeNewswire Inc. • 08/08/2024 08:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/24/2024 04:15:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/23/2024 10:45:24 AM
- Cellectar Biosciences’ Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom’s Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months • GlobeNewswire Inc. • 07/23/2024 10:40:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/22/2024 10:45:16 AM
- Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million • GlobeNewswire Inc. • 07/22/2024 10:40:00 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 07/11/2024 09:37:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2024 09:15:21 PM
- Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom’s Macroglobulinemia Market Landscape • GlobeNewswire Inc. • 06/27/2024 10:40:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:04:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:04:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:03:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:02:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:01:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:01:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:00:17 PM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM